Work

SEZ6L2 expression and clinical relevance in colorectal cancer: insights from NHANES urinary lead epidemiology and multi-omics analyses

Year: 2026
Type: article
Abstract: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide. Heavy metal pollution poses a serious threat to human health; however, its specific role and molecular mechanisms in the development and progression of CRC remain unclear. A total of 107,622 participants were identified from the NHANES database. Following the exclusion of individuals with missing urinary heavy metal measurements or incomplete data on covariates (age, sex, race, education, marital status, and poverty income ratio), the final analytic sample consisted of 14,341 participants. To account for the complex multistage sampling design of NHANES and adjust for potential confounders, survey-weighted logistic regression models were employed.After simultaneously adjusting for age, sex, race, education, marital status, and poverty income ratio, creatinine-corrected urinary lead was significantly positively associated with colorectal cancer. This finding suggests that lead may be a key heavy metal associated with colorectal cancer. By integrating multiple omics databases (CTD, GEO, TCGA, and GeneCards) and performing cross-screening, we identified SEZ6L2 as a key gene linking lead exposure to colorectal cancer. We then used single-cell and spatial transcriptomics to characterize the expression heterogeneity and spatial distribution of SEZ6L2 in the tumor microenvironment. Its potential biological functions were further explored through CellChat cell-cell communication analysis, scMetabolism metabolic activity analysis, and SCENIC transcriptional regulatory network analysis. SEZ6L2 protein expression and its association with prognosis were evaluated by immunohistochemical staining of 180 paraffin-embedded tissue microarray samples. Finally, potential drugs targeting SEZ6L2 were screened by molecular docking and 200 ns molecular dynamics simulation. Through the use of survey-weighted logistic regression analysis, lead was identified as a key heavy metal associated with colorectal cancer. Cross-analysis of multi-omics data identified 115 key genes affected by lead exposure in colorectal cancer. Prognostic analysis based on TCGA showed that SEZ6L2 was the only gene significantly associated with poor overall survival. According to the MIB2 database, lead was predicted to bind to the CUB2 and SUSHI2 domains of SEZ6L2. Single-cell transcriptomics showed that SEZ6L2 was predominantly enriched in tumor epithelial cells and was negatively correlated with the infiltration of multiple immune cell types, suggesting a role in shaping an immunosuppressive tumor microenvironment. CellChat analysis further showed that high SEZ6L2 expression in epithelial cells enhanced communication with fibroblasts. Spatial transcriptomic co-localization analysis confirmed that genes positively correlated with SEZ6L2 were enriched in cell proliferation pathways, whereas negatively correlated genes were enriched in immune response-related functions. scMetabolism analysis indicated that the SEZ6L2-high subgroup exhibited a dual-activation metabolic phenotype involving both glycolysis and lipid synthesis, together with activation of the cytochrome P450-mediated xenobiotic metabolism pathway, implying a possible association with chemotherapy resistance. SCENIC analysis identified PPARG and NR1H4 as candidate transcriptional regulators associated with the hypermetabolic phenotype. Immunohistochemical analysis of tissue microarrays showed that SEZ6L2 protein was significantly overexpressed in colorectal cancer tissues; high expression was positively correlated with maximal tumor diameter, lymph node metastasis and the Ki67 proliferation index. Patients with high SEZ6L2 protein expression also had a significantly poorer prognosis (P = 0.035). Finally, molecular docking and molecular dynamics simulations suggested a possible interaction between doxorubicin and the SEZ6L2 protein, indicating that doxorubicin may serve as a candidate therapeutic agent targeting SEZ6L2. SEZ6L2 may link lead exposure to colorectal cancer progression through metabolic reprogramming and remodeling of the tumor microenvironment. High SEZ6L2 expression was associated with greater tumor diameter, lymph node metastasis, a higher Ki67 index, and poorer prognosis. Doxorubicin may be a therapeutic candidate for colorectal cancers with high SEZ6L2 expression.
Language: English
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7237359781
FWCI:
Cites:
Cited by:
Related to: